paclitaxel and am 630
paclitaxel has been researched along with am 630 in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Deng, L; Guindon, J; Hohmann, AG; Makriyannis, A; Thakur, GA; Vemuri, VK; White, FA | 1 |
| Cornett, BL; Deng, L; Guindon, J; Hohmann, AG; Mackie, K; Makriyannis, A | 1 |
| Calixto, JB; Costa, R; Freitas, CS; Manjavachi, MN; Matias, DO; Passos, GF; Segat, GC | 1 |
Other Studies
3 other study(ies) available for paclitaxel and am 630
| Article | Year |
|---|---|
The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.
Topics: Animals; Benzylamines; Chromones; Cisplatin; Cryopyrin-Associated Periodic Syndromes; Cyclams; Disease Models, Animal; Heterocyclic Compounds; Hyperalgesia; Indoles; Male; Paclitaxel; Peripheral Nervous System Diseases; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Receptors, CXCR4; Signal Transduction; Time Factors; Treatment Outcome | 2012 |
Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Chemokine CCL2; Chromones; Disease Models, Animal; Dronabinol; Female; Hyperalgesia; Indoles; Male; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; Random Allocation; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; RNA, Messenger; Spinal Cord; Tumor Necrosis Factor-alpha | 2015 |
Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Cannabinoid Receptor Modulators; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Indoles; Male; Neuralgia; Paclitaxel; Pain Threshold; Peripheral Nervous System Diseases; Piperidines; Polycyclic Sesquiterpenes; Pyrazoles; Random Allocation; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Sesquiterpenes; Spinal Cord | 2017 |